Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Randomized Phase II Study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft Versus Host Disease

This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.

Study Overview

• Status: Recruiting
• Conditions: Chronic Graft Versus Host Disease
• Intervention / Treatment: Procedure: Biospecimen Collection; Drug: Placebo Administration; Drug: Belumosudil; Other: Electronic Health Record Review

Detailed Description

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive belumosudil orally (PO) daily (QD) or twice daily (BID) if taken with strong CYP3A inducers or proton pump inhibitors for days 1 through 28 of each cycle. Cycles repeat every 28 days for a total of 11 cycles, followed by one cycle of tapering prior to discontinuation, in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive a placebo PO QD or BID if taken with strong CYP3A inducers or proton pump inhibitors for days 1 through 28 of each cycle. Cycles repeat every 28 days for a total of 11 cycles, followed by one cycle of tapering prior to discontinuation, in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection on study.

Patients follow up after completion of study medication at 30 days, and at 60 days if 12 cycles are completed.

• Study Type: Interventional
• Enrollment (Estimated): 82
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Chloe Te; Phone Number: 206-667-4196; Email: cte@fredhutch.org

Study Locations

• United States
  • Florida
    • Tampa, Florida, United States, 33612
      • Not yet recruiting
      • Moffitt Cancer Center
      • Principal Investigator: Joseph Pidala, MD, PhD
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Not yet recruiting
      • Dana Farber Cancer Institute
      • Principal Investigator: Corey Cutler, MD, MPH
    • Boston, Massachusetts, United States, 02114
      • Not yet recruiting
      • Mass General Cancer Center
      • Principal Investigator: Zachariah Defilipp, MD
  • New York
    • New York, New York, United States, 10065
      • Not yet recruiting
      • Memorial Sloan Kettering Cancer Center
      • Principal Investigator: Doris Ponce, MD
  • Washington
    • Seattle, Washington, United States, 98109
      • Recruiting
      • Fred Hutch/University of Washington Cancer Consortium
      • Principal Investigator: Stephanie Lee, MD, MPH
      • Contact: Chloe Te; Phone Number: 206-667-4196; Email: cte@fredhutch.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• At least one diagnostic or distinctive cGVHD manifestation(s), with a clinical diagnosis of cGVHD,but patients do not need to meet National Institute of Health (NIH) criteria for cGVHD
• If eye involvement only, cGVHD must be confirmed on exam by an ophthalmologist or optometrist

• No new immune suppressive therapy added within preceding 2 weeks prior to study enrollment for any indication

  • Continuation of agents previously given as either GVHD prophylaxis or acute/late acute GVHD therapy are permitted. Modification of dose of these agents for targeting of therapeutic drug levels is permitted, as are decreases in existing prednisone dose based on routine clinical tapering practices. Increases in prednisone are not allowed in the 2 weeks prior to enrollment
• Age 18 and older
• Karnofsky performance score >= 70
• Able to take oral medications
• Signed informed consent
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
• Total bilirubin =< 1.5 x ULN
• Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2
• Female subjects of childbearing potential have a negative serum or urine pregnancy test at screening. Females of childbearing potential are defined as sexually mature females without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, females who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression

• Sexually active females of childbearing potential enrolled in the study must agree to use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes:

  • Intrauterine device (IUD) plus one barrier method
  • Stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus one barrier method
  • 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm); or
  • A vasectomized partner
• For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug
• No evidence of active malignancy

Exclusion Criteria:

• Any systemic immune suppressive treatment for cGVHD (topical or local therapies are allowed)
• Plan to start systemic immune suppressive therapy for cGVHD or increase steroid dose within 14 days after planned start of study medication
• 0.25 mg/kg/day or higher prednisone dose at time of screening
• History of non-compliance that in the investigator's opinion would interfere with study participation
• Uncontrolled psychiatric illness
• Female subject who is pregnant or breast feeding
• Previous therapy with belumosudil
• Known allergy/sensitivity to belumosudil or any other ROCK2 inhibitor
• Treatment with another investigational agent within 28 days (or 5 half-lives, whichever is greater) of enrollment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm I (Belumosudil); Patients receive belumosudil PO QD or BID if taken with strong CYP3A inducers or proton pump inhibitors for days 1 through 28 of each cycle. Cycles repeat every 28 days for a total of 11 cycles, followed by one cycle of tapering prior to discontinuation, in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study.	Procedure: Biospecimen Collection; Undergo blood sample collection; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Drug: Belumosudil; Given PO; Other Names: SLx-2119; KD025; KD 025; KD-025; Rho-associated Coiled-coil Kinase 2 Inhibitor KD025; ROCK-II Inhibitor KD025; ROCK2 Inhibitor KD025; SLx 2119; SLx2119; Other: Electronic Health Record Review; Ancillary study
Placebo Comparator: Arm II (Placebo); Patients receive a placebo PO QD or BID if taken with strong CYP3A inducers or proton pump inhibitors for days 1 through 28 of each cycle. Cycles repeat every 28 days for a total of 11 cycles, followed by one cycle of tapering prior to discontinuation, in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study.	Procedure: Biospecimen Collection; Undergo blood sample collection; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Drug: Placebo Administration; Given PO; Other: Electronic Health Record Review; Ancillary study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to start of subsequent systemic immune suppressive treatment for chronic graft versus host disease (cGVHD)	Systemic therapies include any systemic agent given for a cGVHD indication, including extracorporeal photopheresis. Will use Gray's test. Point estimates of new systemic immunosuppressive use will be obtained using cumulative incidence estimates.	From first dose of study medication to starting a new systemic immunosuppressive agent for cGVHD therapy, up to 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Event-free survival	Point estimates will be obtained using the method of Kaplan and Meier and the log-rank test will be used to assess the difference between treatment groups.	From randomization to death, malignancy relapse or addition of a new systemic immune suppressive therapy, up to 12 months or end of study
Overall survival	Point estimates will be obtained using the method of Kaplan and Meier and the log-rank test will be used to assess the difference between treatment groups.	Up to 12 months or end of study
Rate of relapse	Point estimates will be obtained using the method of Kaplan and Meier and the log-rank test will be used to assess the difference between treatment groups.	Up to 12 months or end of study

Collaborators and Investigators

• Sponsor: Fred Hutchinson Cancer Center
• Collaborators: Sanofi
• Investigators: Principal Investigator: Stephanie Lee, MD, MPH, Fred Hutch/University of Washington Cancer Consortium

Study record dates

Study Major Dates

• Study Start (Actual): December 6, 2023
• Primary Completion (Estimated): May 31, 2027
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: August 10, 2023
• First Submitted That Met QC Criteria: August 10, 2023
• First Posted (Actual): August 18, 2023

Study Record Updates

• Last Update Posted (Actual): December 29, 2023
• Last Update Submitted That Met QC Criteria: December 27, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Bronchitis; Bronchiolitis Obliterans; Bronchiolitis; Organizing Pneumonia; Graft vs Host Disease; Bronchiolitis Obliterans Syndrome; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Kinase Inhibitors; Belumosudil
• Other Study ID Numbers: RG1123523 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium); 20163 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium); NCI-2023-05293 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No